|
EP3195878A1
|
|
Bacterial ghosts for the treatment of cancer
|
|
EP2591798A1
|
|
Vaccine for use in tumor immunotherapy
|
|
US2012034268A1
|
|
Bacterial ghosts for mediating innate immunity
|
|
CN102224237A
|
|
Bacterial ghost (BG) production process using beta-propiolactone (BLP) for final inactivation
|
|
EP2170301A1
|
|
Virus-modified bacteria ghosts
|
|
DE10335796A1
|
|
Closure of bacterial ghosts by bioaffine interactions
|
|
DE10120061A1
|
|
Exopolysaccharidproduktion
|
|
DE10003241A1
|
|
Sealing bacterial ghosts
|
|
DE19937719A1
|
|
New nucleic acid from phage phiCh1, used to create vectors for expressing proteins and polymers in halophilic Archaea
|
|
DE19909770A1
|
|
Bacterial ghosts as carrier and targeting vehicles
|
|
DE19903345A1
|
|
Compartmentalization of recombinant polypeptides in host cells
|
|
WO9906567A1
|
|
Secretion of carrier-bonded proteins into the periplasma and the extracellular space
|
|
US6964845B1
|
|
Thermostable phage lambda operator mutants for regulating gene expression
|
|
DE19603649A1
|
|
Recombinant expression of S-layer proteins
|
